Experimental Ebola treatments at a glance

October 6, 2014 7:41 PM

3 0

— Chimerix Inc.'s brincidofovir, being used on the Dallas Ebola patient, is an oral medicine developed to treat other types of viruses. It is in late-stage testing for cytomegalovirus. Durham, North Carolina-based Chimerix is also developing it as a smallpox treatment. Laboratory tests suggest it may be active against Ebola.

— ZMapp from San Diego-based Mapp Pharmaceuticals was developed specifically as an Ebola treatment, a cocktail of antibodies engineered to recognize the virus and bind to infected cells. Supplies are exhausted; work is underway to produce more.

Read more

To category page